Posted by Michael Wonder on 09 Dec 2015
EMA started the evaluation of Richter’s marketing authorisation application for biosimilar pegfilgrastim
8 December 2015 - Gedeon Richter Plc. today announced that the EMA has accepted Richter's regulatory submission for its proposed biosimilar to Amgen's Neulasta (pegfilgrastim).
For more details, go to: https://www.richter.hu/en-US/pressroom/press-release/Pages/press-releases/pr151208.aspx
